
Oncology NEWS International
- Oncology NEWS International Vol 7 No 8
- Volume 7
- Issue 8
Cryopreservation of Semen Tried in Adolescent Males
NIAGARA-ON-THE-LAKE, Ontario, Canada--While the collection of sperm from adult males prior to cancer treatment is a routine matter, the same issue has not yet been regularly introduced into adolescent clinics.
NIAGARA-ON-THE-LAKE, Ontario, Canada--While the collection of sperm from adult males prior to cancer treatment is a routine matter, the same issue has not yet been regularly introduced into adolescent clinics.
"We should be prepared to offer sperm banking to patients who are about to receive chemotherapy or radiotherapy that might damage spermatogenesis," said Jørn Müller, MD, Department of Growth and Reproduction, The Juliane Marie Centre, Copenhagen, Denmark.
He noted that this has not commonly been an option for young men, "and yet the technology is available to preserve their sperm and also to use very few sperm to fertilize an egg," he said at the 5th International Conference for Long-Term Complications of Treatment of Children and Adolescents for Cancer, hosted by Roswell Park Cancer Institute.
The Danish group has examined this topic for 3 years in adolescent males. Several concerns have been addressed in the study, including the often short time between the cancer diagnosis and required therapy, the difficulty in addressing the topic with a young adult male and his parents, the large variation in physical maturation in adolescent males, and the limited experience in semen analysis and cryopreservation in adolescent males.
The researchers approached 33 families. Of these, 15 boys were able to produce semen samples for cryopreservation (via masturbation, penile vibratory stimulation, or electroejaculation).
The age range was 13 to 18 years, with a mean of 16. Each patient had a new diagnosis of cancer or relapsed disease. The group included seven patients with acute lymphoblastic leukemia, three with Hodgkins lymphoma, one with non-Hodgkins lymphoma, two with osteosar-coma, one with a central nervous system tumor, and one with Wilms tumor.
Semen samples from two of the boys (13 and 17 years old) did not contain spermatozoa and were not preserved. The remaining 24 samples were analyzed for volume and viable sperm.
60 Million Sperm per Sample
The median volume of semen delivered was 3.0 mL (range, 0.7 to 8.3 mL), and the median volume of sperm cryopreserved was 2.5 mL (range, 0.6 to 7.2 mL). The median number of spermatozoa in the samples was 60 million (range, 1.6 to 210 million). In comparison, a normal, fertile man would produce about 250 million spermatozoa in a similar sample.
"In the lowest age range, there was a lower number of spermatozoa as well as decreased semen volume," Dr. Müller noted.
He said that studies have shown that adolescents, even those as young as 11, may also have semen in their urine, and although these sperm are passively transmitted, this could offer another way to bank sperm for the future.
"This study shows that cryopreservation of semen in young adults is possible and suggests that the analysis of spermatogenesis in males over the age of 10 should be considered before cancer treatment. It offers these young men the possibility that they can preserve their ability to father children," Dr. Müller concluded.
Articles in this issue
almost 28 years ago
Taxol, Gemzar, Other Therapies Studied in Metastatic Bladder Canceralmost 28 years ago
Medicare+Choice Opens Certificationalmost 28 years ago
Consumer Advocates Win a Voice in NCI Programsalmost 28 years ago
Paclitaxel Shows Antiangiogenesis Effects in Mouse Modelalmost 28 years ago
Henney Nominated for FDA Commissioneralmost 28 years ago
FDA Approves ImageChecker Computer Systemalmost 28 years ago
Pittsburgh Seeks Breast Cancer Patients for Study on Copingalmost 28 years ago
Octreotide Imaging Improves Staging of Hodgkin’s Diseasealmost 28 years ago
Tobacco Contributions Are Linked to Votes Against Tobacco Billalmost 28 years ago
Kaposi’s Sarcoma, Cervical Dysplasia Both Improve With Anti-HIV TherapyRelated Content



99 Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial




















































